AstraZeneca Plc has announced plans to invest $200 million in a new manufacturing facility in China Medical City, Taizhou, Jiangsu province. The site will produce both intravenous and oral solid medicines for the company’s business in China. ---Subscribe to MedNous to access this article--- Company News